Evogene Ltd. (EVGN) stock
EVGNNasdaqAgricultural ChemicalsFiscal year ends December 31
$0.34−0.05 (-13.17%)
Close on Nov 17, 2026Market cap $2.97MP/E 0.3Yield –
Evogene operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
For fiscal 2025 it was -$14.03M. The highest annual figure on record is -$14.03M in fiscal 2025.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$14.03M | – |
| FY2024 | Dec 31, 2024 | -$18.80M | – |
| FY2023 | Dec 31, 2023 | -$22.23M | – |
| FY2022 | Dec 31, 2022 | -$26.94M | – |
| FY2021 | Dec 31, 2021 | -$30.95M | – |
| FY2020 | Dec 31, 2020 | -$24.81M | – |
| FY2019 | Dec 31, 2019 | -$21.17M | – |
| FY2018 | Dec 31, 2018 | -$19.99M | – |
| FY2017 | Dec 31, 2017 | -$21.95M | – |
| FY2016 | Dec 31, 2016 | -$21.09M | – |
| FY2015 | Dec 31, 2015 | -$17.92M | – |
See a number that looks wrong?